CO6341479A2 - Péptidos agonistas de crhr2 y usos de estos - Google Patents
Péptidos agonistas de crhr2 y usos de estosInfo
- Publication number
- CO6341479A2 CO6341479A2 CO11061124A CO11061124A CO6341479A2 CO 6341479 A2 CO6341479 A2 CO 6341479A2 CO 11061124 A CO11061124 A CO 11061124A CO 11061124 A CO11061124 A CO 11061124A CO 6341479 A2 CO6341479 A2 CO 6341479A2
- Authority
- CO
- Colombia
- Prior art keywords
- crhr2
- treatment
- relates
- present
- peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
Abstract
La presente invención se relaciona con péptidos nuevos que son agonistas selectivos del receptor de la hormona de liberación de corticotropina tipo 2 (CRHR2) y las composiciones de éstos para el tratamiento, mejora o inhibición de afecciones cardiovasculares que incluyen, pero sin limitarse a, la insuficiencia cardíaca. El péptido agonista nuevo comprende, preferentemente, modificaciones que incluyen péptidos pegilados. Además, la presente invención se relaciona con los métodos para el tratamiento y prevención de una enfermedad o trastorno relacionado con la actividad de CRHR2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11123308P | 2008-11-04 | 2008-11-04 | |
US17889009P | 2009-05-15 | 2009-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6341479A2 true CO6341479A2 (es) | 2011-11-21 |
Family
ID=41509080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11061124A CO6341479A2 (es) | 2008-11-04 | 2011-05-18 | Péptidos agonistas de crhr2 y usos de estos |
Country Status (20)
Country | Link |
---|---|
US (1) | US10040838B2 (es) |
EP (1) | EP2362881B1 (es) |
JP (1) | JP2012508014A (es) |
KR (1) | KR20110091720A (es) |
CN (1) | CN102272151B (es) |
AU (1) | AU2009313619A1 (es) |
BR (1) | BRPI0921640A2 (es) |
CA (1) | CA2742710A1 (es) |
CO (1) | CO6341479A2 (es) |
CR (1) | CR20110305A (es) |
EA (1) | EA201170647A1 (es) |
EC (1) | ECSP11011099A (es) |
ES (1) | ES2723098T3 (es) |
IL (1) | IL212685A0 (es) |
MX (1) | MX2011004718A (es) |
NI (1) | NI201100087A (es) |
NZ (1) | NZ592670A (es) |
SG (1) | SG171957A1 (es) |
WO (1) | WO2010053990A2 (es) |
ZA (1) | ZA201104160B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010053990A2 (en) | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
AU2010315131A1 (en) * | 2009-11-04 | 2012-05-31 | Janssen Pharmaceutica Nv | Method for treating heart failure with stresscopin-like peptides |
EP2814513B1 (en) | 2012-02-14 | 2017-12-20 | The Regents of The University of California | Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions |
JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2127458T3 (es) | 1989-11-06 | 1999-04-16 | Cell Genesys Inc | Produccion de proteinas utilizando recombinacion homologa. |
US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US6552170B1 (en) * | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
SG89295A1 (en) * | 1991-03-15 | 2002-06-18 | Amgen Inc | Pegylation of polypeptides |
US5554728A (en) * | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
EP0922446A1 (en) * | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
US6420339B1 (en) * | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US20020082409A1 (en) * | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
US6673580B2 (en) * | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
NZ524477A (en) * | 2001-03-15 | 2004-11-26 | Res Dev Foundation | Urocortin-III and uses thereof |
ATE333290T1 (de) | 2001-05-21 | 2006-08-15 | Injet Digital Aerosols Ltd | Zusammensetzungen für die freisetzung von protein auf dem pulmonalen weg |
EP1461351A4 (en) * | 2001-12-03 | 2006-09-13 | Metabolex Inc | METHOD AND REAGENT FOR DIABETES DIAGNOSIS AND TREATMENT |
US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
CN100480267C (zh) * | 2002-01-16 | 2009-04-22 | 宝洁公司 | 促肾上腺皮质激素释放因子2受体激动剂 |
KR100512483B1 (ko) * | 2003-05-07 | 2005-09-05 | 선바이오(주) | 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법 |
GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
EP1675620B1 (en) * | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymer derivatives |
EP1768686A4 (en) * | 2004-06-12 | 2007-11-14 | Bayer Pharmaceuticals Corp | PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US7815905B2 (en) * | 2006-01-27 | 2010-10-19 | Research Development Foundation | Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors |
EP2114437A2 (en) * | 2006-10-16 | 2009-11-11 | ConjuChem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
US20100249027A1 (en) | 2007-05-25 | 2010-09-30 | William Henry | Crf conjugates with extended half-lives |
RU2010114031A (ru) | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства |
MX2010002753A (es) | 2007-09-14 | 2010-03-30 | Basf Plant Science Gmbh | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas. |
WO2010053990A2 (en) | 2008-11-04 | 2010-05-14 | Janssen Pharmaceutica Nv | Crhr2 peptide agonists and uses thereof |
CN102781965A (zh) | 2009-10-06 | 2012-11-14 | 安吉奥开米公司 | 用于转运治疗剂的组合物和方法 |
AU2010315131A1 (en) * | 2009-11-04 | 2012-05-31 | Janssen Pharmaceutica Nv | Method for treating heart failure with stresscopin-like peptides |
ES2855110T3 (es) | 2011-07-18 | 2021-09-23 | The Us Secretary Department Of Health And Human Services National Institutes Of Health | Métodos y composiciones para la inhibición de una patología asociada a poliomavirus |
-
2009
- 2009-11-04 WO PCT/US2009/063276 patent/WO2010053990A2/en active Application Filing
- 2009-11-04 KR KR1020117012435A patent/KR20110091720A/ko not_active Application Discontinuation
- 2009-11-04 SG SG2011040755A patent/SG171957A1/en unknown
- 2009-11-04 CN CN200980154228.3A patent/CN102272151B/zh not_active Expired - Fee Related
- 2009-11-04 EP EP09748922.3A patent/EP2362881B1/en active Active
- 2009-11-04 BR BRPI0921640A patent/BRPI0921640A2/pt not_active IP Right Cessation
- 2009-11-04 ES ES09748922T patent/ES2723098T3/es active Active
- 2009-11-04 AU AU2009313619A patent/AU2009313619A1/en not_active Abandoned
- 2009-11-04 EA EA201170647A patent/EA201170647A1/ru unknown
- 2009-11-04 NZ NZ592670A patent/NZ592670A/xx not_active IP Right Cessation
- 2009-11-04 US US12/612,548 patent/US10040838B2/en active Active
- 2009-11-04 MX MX2011004718A patent/MX2011004718A/es not_active Application Discontinuation
- 2009-11-04 JP JP2011535643A patent/JP2012508014A/ja active Pending
- 2009-11-04 CA CA2742710A patent/CA2742710A1/en not_active Abandoned
-
2011
- 2011-05-04 IL IL212685A patent/IL212685A0/en unknown
- 2011-05-04 NI NI201100087A patent/NI201100087A/es unknown
- 2011-05-18 CO CO11061124A patent/CO6341479A2/es active IP Right Grant
- 2011-06-02 EC EC2011011099A patent/ECSP11011099A/es unknown
- 2011-06-03 ZA ZA2011/04160A patent/ZA201104160B/en unknown
- 2011-06-06 CR CR20110305A patent/CR20110305A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CR20110305A (es) | 2011-11-10 |
CN102272151A (zh) | 2011-12-07 |
NI201100087A (es) | 2011-10-25 |
IL212685A0 (en) | 2011-07-31 |
MX2011004718A (es) | 2011-07-28 |
EP2362881B1 (en) | 2019-03-13 |
BRPI0921640A2 (pt) | 2019-09-24 |
US10040838B2 (en) | 2018-08-07 |
KR20110091720A (ko) | 2011-08-12 |
US20100130424A1 (en) | 2010-05-27 |
JP2012508014A (ja) | 2012-04-05 |
EA201170647A1 (ru) | 2011-12-30 |
AU2009313619A1 (en) | 2010-05-14 |
CA2742710A1 (en) | 2010-05-14 |
EP2362881A2 (en) | 2011-09-07 |
WO2010053990A3 (en) | 2010-07-01 |
ECSP11011099A (es) | 2011-07-29 |
NZ592670A (en) | 2013-01-25 |
SG171957A1 (en) | 2011-07-28 |
ES2723098T3 (es) | 2019-08-21 |
ZA201104160B (en) | 2012-11-28 |
CN102272151B (zh) | 2014-08-20 |
WO2010053990A2 (en) | 2010-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001552A1 (es) | Agonistas duales acilados de glp-1/glp-2. | |
ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
CO6341479A2 (es) | Péptidos agonistas de crhr2 y usos de estos | |
CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
CL2011001578A1 (es) | Anticuerpo que inhibe selectivamente al receptor del peptido relacionado al gen de la calcitonina ( cgrp r) humano; polinucleotido que lo codifica; vector; celula; metodo de produccion; composicion farmaceutica que lo comprende; y su uso para tratar un medicamento para tratar una condicion asociada con cgrp r en un paciente, como migraña. | |
ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
GT200800198A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1. | |
AR078445A1 (es) | Agonistas del peptido natriuretico tipo b (npr -b) | |
AR072159A1 (es) | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad | |
EA201001253A1 (ru) | N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d | |
CR11042A (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
CL2012001722A1 (es) | Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes. | |
AR069136A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos | |
UY31619A1 (es) | Compuestos espiro como antagonistas del receptor npy y5 | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
CR20120415A (es) | Polipéptidos agonistas que se enlazan a dr5 | |
PE20091193A1 (es) | Proteinas humanas de union a antigenos del gm-csf | |
CO6541617A2 (es) | Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina | |
CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
PE20130815A1 (es) | Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos | |
EA201070725A1 (ru) | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона | |
ZA202107825B (en) | Pharmaceutical parenteral composition of dual glp1/2 agonist | |
PT1988914E (pt) | Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |